Touro Scholar
NYMC Faculty Publications

Faculty

6-20-2017

Ketamine Use for Successful Resolution of Post-ERCP Acute
Pancreatitis Abdominal Pain
S Agerwala
D Sundarapandiyan
Garret Weber
New York Medical College

Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs
Part of the Digestive System Diseases Commons, and the Therapeutics Commons

Recommended Citation
Agerwala, S., Sundarapandiyan, D., & Weber, G. (2017). Ketamine Use for Successful Resolution of PostERCP Acute Pancreatitis Abdominal Pain. Case Reports in Anesthesiology, 2017, 7845358.
https://doi.org/10.1155/2017/7845358

This Article is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for
inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information,
please contact touro.scholar@touro.edu.

Hindawi
Case Reports in Anesthesiology
Volume 2017, Article ID 7845358, 3 pages
https://doi.org/10.1155/2017/7845358

Case Report
Ketamine Use for Successful Resolution of Post-ERCP Acute
Pancreatitis Abdominal Pain
Suneel M. Agerwala, Divya Sundarapandiyan, and Garret Weber
New York Medical College, Valhalla, NY, USA
Correspondence should be addressed to Garret Weber; garret.weber@wmchealth.org
Received 26 March 2017; Accepted 25 May 2017; Published 20 June 2017
Academic Editor: Alparslan Apan
Copyright © 2017 Suneel M. Agerwala et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
We report a case in which a patient with intractable pain secondary to post-endoscopic retrograde cholangiopancreatography
(ERCP) acute pancreatitis is successfully treated with a subanesthetic ketamine infusion. Shortly after ERCP, the patient reported
severe stabbing epigastric pain. She exhibited voluntary guarding and tenderness without distension. Amylase and lipase levels
were elevated. Pain persisted for hours despite hydromorphone PCA, hydromorphone boluses, fentanyl boluses, and postprocedure
anxiolytics. Pain management was consulted and a ketamine infusion was trialed, leading to a dramatic reduction in pain. This case
suggests that ketamine may be a promising option in treating intractable pain associated with ERCP acute pancreatitis.

1. Introduction
While subanesthetic ketamine infusion has been used to
manage postoperative pain and opioid resistant pain, as well
as acute pain and procedural sedation in the emergency
department and in the pediatric population, there has been
no study examining its use in ERCP pancreatitis in the adult
population. We present a novel case in which intractable
post-ERCP acute pancreatitis pain in an adult patient was
successfully managed using a subanesthetic dose of ketamine
infusion.

2. Case Description
The pain management service was consulted for a 24-year-old
female with past medical history notable for polycystic ovarian syndrome. She presented with intractable abdominal
pain, status post-endoscopic retrograde cholangiopancreatography (ERCP), for suspected choledocholithiasis/postcholecystectomy syndrome. Six weeks earlier, the patient
underwent elective cholecystectomy and was discharged
home uneventfully, with pain well controlled on oral analgesics. On the day prior to admission, the patient awoke
with severe abdominal pain and presented to the emergency
department. Her pain was reported as 10/10 on the numerical

rating scale in severity and was described as sharp, located in
her mid-abdomen above the umbilicus, radiating to the right
upper quadrant and back, and accompanied by nausea. She
was then admitted as an inpatient for further workup.
On hospital day #1 her pain was treated with morphine
sulfate IV 3 mg q4h prn. She received four doses. On hospital
day #2 the patient complained of persistent pain and her pain
regimen was switched to Hydromorphone IV 0.2 mg q4h
PRN. She was given 2 doses on hospital day #2. Abdominal
imaging, which included right upper quadrant ultrasound
and abdominal CT, revealed intrahepatic and extrahepatic
bile duct dilatation, which was suspicious for possible biliary
stones. Amylase and lipase were within normal limits. The
primary team decided to pursue ERCP given the inconclusive
workup.
Prior to the ERCP, the patient was given Hydromorphone
IV 0.5 mg. She then underwent general anesthesia with endotracheal tube, with an uneventful anesthetic course. Anesthesia was induced with propofol and lidocaine and maintained
with propofol boluses. She was also given a total of 100 mcg
of fentanyl. Her ERCP showed diffuse common bile duct
dilation of 12 mm and a possible amorphous filling defect in
the common bile duct. The common bile duct was ballooned,
a sphincterotomy was performed, and the pancreatic duct was
stented. She was then extubated and brought to the PACU.
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In the PACU, the patient complained of severe, excruciating, stabbing epigastric pain and demonstrated voluntary
guarding and tenderness without distension. Amylase and
lipase levels were elevated to 199 and 121, respectively, and
her pain was attributed to post-ERCP acute pancreatitis. The
anesthesia service immediately ordered Hydromorphone IV
2 mg, fentanyl 100 mcg, and midazolam 2 mg. With her pain
still uncontrolled, approximately 1 hour later, while still in the
PACU, the patient was given over the next hour one additional dose each of midazolam 2 mg, fentanyl 100 mcg, and
hydromorphone 2 mg. Hydromorphone PCA with demand
dosing 0.2 mg every 10 minutes was then started. The patient’s
pain remained uncontrolled over the next three hours, so
an additional nurse-administered hydromorphone bolus was
given. The pain management service was consulted at this
point.
Given the patient’s persistent pain despite hydromorphone PCA, hydromorphone boluses, fentanyl boluses, and
postprocedural anxiolytics, a decision was made to start
ketamine infusion (3 mcg/kg/min) at low dose for analgesia.
The patient then experienced significantly improved pain
which allowed her to leave the PACU stably and comfortably.
This was accompanied by a reduction in PCA use overnight
requiring only one demand dose and no additional nurseadministered boluses. The next morning she expressed that
the pain had resolved to a feeling of mild soreness. On
hospital day #4, the ketamine drip was discontinued and pain
was controlled to a minimum. On hospital day #5, her labs
had normalized, she was tolerating diet, and was discharged
home.

3. Discussion
Current management for pain secondary to acute pancreatitis includes NSAIDs, acetaminophen, and opioids [1]. We
present a case where traditional management for this type of
pain was insufficient for analgesia and where a subanesthetic
ketamine infusion was used to successfully alleviate pain.
A recent cohort study in pediatric pain management
examined the use of low-dose ketamine infusion in the treatment of acute pain for multiple different diagnoses. The study
showed reduction in pain scores after ketamine infusion for a
pooled “inflammatory diseases” group that included patients
with Crohn’s disease and pancreatitis, in general, but did not
delineate between the two diseases [2]. To our knowledge, our
case study is the first report of ketamine used as an analgesic
to treat intractable post-ERCP, specific, pancreatitis pain in
the adult population.
The incidence of post-ERCP pancreatitis (PEP) is estimated to be 3.47%. Risk factors include female gender,
young age, sphincter of Oddi dysfunction, absence of chronic
pancreatitis, and history of prior PEP. Prevention in highrisk patients includes pharmacologic prophylaxis using antiinflammatory medication and improved endoscopic techniques, such as stenting and faster biliary cannulation time
[3].
In order to diagnose acute pancreatitis, two of the main
three features must be confirmed. These features are abdominal pain typical for acute pancreatitis, serum amylase/lipase
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greater than 3 times the upper normal limit, and evidence of
acute pancreatitis on CT scan. Initial assessment of severity
is important for planning proper management. Mild acute
pancreatitis is defined by lack of organ failure, moderate
severity includes transient (<48 hr) organ failure, and severe
is characterized by persistent (>48 hr) organ failure [4].
Analgesia does not modify the course or outcome of
acute pancreatitis but supports patient comfort and patientreported outcomes. Opioids, commonly used to treat pain
in acute pancreatitis, work on the mu receptor pathway,
both peripherally and centrally, to modulate the nociceptive
response and perception of pain [5].
Classically, ketamine has been used for procedural sedation and postoperative pain. When given at anesthetic doses
ketamine causes analgesia, amnesia, and sedation while
having relatively little effect on respiration and overall hemodynamics [6]. At subanesthetic doses, the drug has been
found to be effective in achieving analgesia in opioid resistant
patients [7].
Ketamine’s therapeutic effects have long been attributed
to its ability to reversibly block the activity of N-methyl-Daspartate (NMDA) receptors (NR). NR hyperactivity leads to
sensitization to noxious stimuli and desensitization to opioids. Thus, blocking this pathway has dramatic effects on
analgesia and opioid unresponsiveness. In chronic pain states,
central and peripheral sensitization of pain pathways can
cause the experience of pain to decouple from an appropriate
stimulus. NRs are implicated in the plasticity that leads to sensitization, and blocking this plasticity with ketamine may help
in chronic pain states. In the same way opioid receptors may
be attenuated through NR-dependent mechanisms, leading
to opioid tolerance. Blockade of this pathway may prevent,
reduce, or delay desensitization to opioids [8, 9].
There are other pathways that may contribute to the
analgesic effects of ketamine. An increase in substance 𝑃
receptors has been implicated in greater pain sensitivity and
loss of substance 𝑃 receptors in less pain sensitivity. Ketamine
is known to have a direct inhibitory effect on substance 𝑃
receptors. There is some indication that ketamine may reduce
the release of substance 𝑃 into the synapse. Dopaminergic
pathways may contribute as well. Ketamine has been shown
to increase dopamine signaling, and preliminary evidence
has shown that this is involved in pain reduction. Muscarinic
acetylcholine receptor agonists may increase pain sensitivity
thresholds, and ketamine may have some direct regulatory
effects on those receptors. Serotonergic pathways may have
pronociceptive roles, and ketamine may have an additional
role in modulation [9].
Ketamine’s analgesic effects were shown to be beneficial in
many settings. Using ketamine in conjunction with morphine
was shown to be superior for pain management in the postoperative setting, compared to morphine alone [7]. Ketamine
has also been used in the emergency department for acute
pain, where it showed similar analgesic effects to morphine
[10]. A recent randomized, double-blind, placebo-controlled
trial showed that after a subanesthetic infusion of ketamine
over 15 minutes, patients reported significant decrease in pain
scores for the first 30 minutes when compared to placebo
infusions [11]. Another study showed increased analgesia of

Case Reports in Anesthesiology
ketamine infusion when compared to placebo over a 2-hour
period [12].
One shortcoming is the monitoring necessary to treat a
patient with a subanesthetic ketamine drip. At our institution,
the patient was required to stay in the PACU for 24 hours
because of state regulations that require a higher level of monitoring for patients with a ketamine drip [13]. Additionally,
she was transferred from the PACU to a higher acuity stepdown unit before being transferred to a lower acuity floor.
These rules may vary by state, but the additional resources
for monitoring may be prohibitive for some institutions.
In summary, while ketamine has been used to manage
postoperative pain, opioid resistant pain, and acute pain in
the emergency department, evidence for its use to treat pain
associated with an acute pancreatitis is limited. In our patient
with severe post-ERCP pain associated with acute pancreatitis, opioids and coanalgesics were unable to control her
pain. The addition of a subanesthetic ketamine drip offered
quick and long-lasting analgesia. This could have been due
to the ability of ketamine to modify the effects of opioids or
the direct effect of ketamine itself on the nociceptive system.
The patient was able to comfortably recover from her acute
event, being discharged home with no complications. Further
studies on the safety and the appropriate level of monitoring
at subanesthetic dosing should be investigated to allow for
further use outside of a highly monitored unit.
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